Veritas Pharma Stock Net Asset
| VRTHF Stock | USD 0 0.00 0.00% |
Veritas Pharma fundamentals help investors to digest information that contributes to Veritas Pharma's financial success or failures. It also enables traders to predict the movement of Veritas Pink Sheet. The fundamental analysis module provides a way to measure Veritas Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Veritas Pharma pink sheet.
Veritas |
Veritas Pharma Company Net Asset Analysis
Veritas Pharma's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Veritas Pharma Net Asset | 730 |
Most of Veritas Pharma's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Veritas Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Veritas Pharma has a Net Asset of 730. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net asset for all United States stocks is notably lower than that of the firm.
Veritas Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Veritas Pharma's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Veritas Pharma could also be used in its relative valuation, which is a method of valuing Veritas Pharma by comparing valuation metrics of similar companies.Veritas Pharma is currently under evaluation in net asset category among its peers.
Veritas Fundamentals
| Return On Equity | -5.67 | |||
| Return On Asset | -0.21 | |||
| Current Valuation | 1.77 M | |||
| Shares Outstanding | 71.14 M | |||
| Shares Owned By Insiders | 27.34 % | |||
| Price To Earning | 0.20 X | |||
| Price To Book | 0.43 X | |||
| Gross Profit | (112.96 K) | |||
| EBITDA | (491.67 K) | |||
| Net Income | (2.29 M) | |||
| Cash And Equivalents | 125.27 K | |||
| Total Debt | 765.63 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 0.64 X | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (294.86 K) | |||
| Earnings Per Share | (0.03) X | |||
| Beta | -0.0588 | |||
| Market Capitalization | 1.59 M | |||
| Total Asset | 730 | |||
| Net Asset | 730 |
About Veritas Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Veritas Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Veritas Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Veritas Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Veritas Pink Sheet
Veritas Pharma financial ratios help investors to determine whether Veritas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Veritas with respect to the benefits of owning Veritas Pharma security.